Endosonics CVD unit goes public

Article

The CardioVascular Dynamics subsidiary of Endosonics went publiclast month, floating 3.4 million shares priced at $12 each. Endosonicsplans to retain a 49% stake in Irvine, CA-based CVD, down fromthe 84% share Endosonics previously owned. The stock was

The CardioVascular Dynamics subsidiary of Endosonics went publiclast month, floating 3.4 million shares priced at $12 each. Endosonicsplans to retain a 49% stake in Irvine, CA-based CVD, down fromthe 84% share Endosonics previously owned. The stock was tradingat about $9 a share last week on the NASDAQ exchange.

CVD develops catheters that are used to treat vascular diseasesand are used in conjunction with angioplasty and other interventionalprocedures like vascular stenting and drug delivery. The companyreceived Food and Drug Administration clearance last month forits Active Response Catheter (ARC) product for percutaneous transluminalcoronary angioplasty (PTCA).

Endosonics, of Pleasanton, CA, said last month that it plansto report second-quarter revenues of about $6.7 million, sharplyhigher than the $4 million posted in the same period last year.The company said it will record a one-time charge of $3 millionrelated to the consolidation of its manufacturing operations andthe start-up of production related to its new Five-64 imagingdevices.

Endosonics also plans to form a new subsidiary, MicroSound, todevelop its miniaturized catheter-based imaging technology. Thecompany has developed a transducer/scanhead that is 1 mm in diameter,although product commercialization is several years away.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.